| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer
1 company
Hohl Benjamin is a Chief Financial Officer at Enliven Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 17 sells.
Estimated insider holdings value: $1.6M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 6,250 | $24.61 | $153,828.70 | -100% | -12.3% | -19.9% | |
| Aug 27, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 4,250 | $22.54 | $95,781.83 | -100% | +10.3% | -8.3% | |
| Jul 31, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 991 | $27.53 | $27,280.94 | -100% | +8.1% | -28.7% | |
| Jul 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 5,250 | $26.68 | $140,052.21 | -98.9% | +7.9% | -24.4% | |
| Jul 12, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,000 | $25.07 | $75,195.00 | -100% | +9.0% | -9.3% | |
| Jun 27, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 4,250 | $22.57 | $95,921.55 | -50.8% | +3.3% | -11.8% | |
| May 28, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 4,250 | $23.18 | $98,530.29 | -64.4% | -1.2% | -30.8% | |
| May 3, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,000 | $22.50 | $22,500.00 | -100% | +9.1% | -9.4% | |
| Apr 29, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $16.97 | $55,164.53 | -100% | +49.3% | +4.8% | |
| Apr 11, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 14,000 | $24.72 | $346,148.88 | -57.8% | -3.2% | -30.7% |